Bristol-Myers Squibb Notified Century Therapeutics On Dec 12 To Terminate Collaboration Agreement, Effective March 12, 2025; Co To Evaluate Opportunities In AML And Multiple Myeloma In The Context Of The Ongoing Strategic Review Of Century's...
Bristol-Myers Squibb Notified Century Therapeutics On Dec 12 To Terminate Collaboration Agreement, Effective March 12, 2025; Co To Evaluate Opportunities In AML And Multiple Myeloma In The Context Of The Ongoing Strategic Review Of Century's...
Bristol-Myers Squibb Notified Century Therapeutics On Dec 12 To Terminate Collaboration Agreement, Effective March 12, 2025; Co To Evaluate Opportunities In AML And Multiple Myeloma In The Context Of The Ongoing Strategic Review Of Century's Pre-clinical Pipeline
施贵宝于2023年12月12日通知世纪治疗公司终止合作协议，生效日期为2025年3月12日；公司将在世纪的临床前管道的持续战略审查背景下评估急性髓性白血病和多发性骨髓瘤的机会。
|
Termination of a Material Definitive Agreement |
|
终止重要最终协议 |
On January 7, 2022, Century Therapeutics, Inc. (the "Company") entered into a Research, Collaboration and License Agreement (the "Collaboration Agreement") with Bristol-Myers Squibb Company ("BMS") to collaborate on the research, development and commercialization of induced pluripotent stem cell derived, engineered natural killer cell and/or gamma delta T cell programs for hematologic malignancies.
在2022年1月7日，世纪治疗公司（以下简称"公司"）与施贵宝公司（"BMS"）签署了研究、合作和许可协议（"合作协议"），以合作研究、开发和商业化诱导多能干细胞衍生的工程化自然杀伤细胞和/或伽马δ T细胞项目，用于治疗血液恶性肿瘤。
Following an internal corporate portfolio prioritization process, BMS notified the Company on December 12, 2024 that it would be terminating the Collaboration Agreement in its entirety without cause. The termination will be effective on March 12, 2025. The Company is encouraged by the scientific progress on the programs and will evaluate opportunities in acute myeloid leukemia and multiple myeloma in the context of the ongoing strategic review of Century's pre-clinical pipeline. Both parties will work together in accordance with the termination provisions of the Collaboration Agreement.
在内部企业投资组合优先考虑过程中，BMS于2024年12月12日通知公司将无理由终止整个合作协议。该终止将于2025年3月12日生效。公司对这些项目的科学进展感到鼓舞，并将在世纪临床前管道的持续战略审查背景下评估急性髓性白血病和多发性骨髓瘤的机会。双方将根据合作协议的终止条款共同工作。